Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 791Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Pradaxa

PharmaCompass

01

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Hematology

Currency : USD

2020 Revenue in Millions : 1,777

2019 Revenue in Millions : 1,821

Growth (%) : -2

blank

02

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Hematology

Currency : USD

2021 Revenue in Millions : 1,451

2020 Revenue in Millions : 1,777

Growth (%) : -12

blank

03

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 1,201

2021 Revenue in Millions : 1,451

Growth (%) : -17

blank

04

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Hematology

Currency : USD

2023 Revenue in Millions : 899

2022 Revenue in Millions : 1,201

Growth (%) : -24

blank

05

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Blood Disorders

Currency : USD

2016 Revenue in Millions : 1,468

2015 Revenue in Millions : 1,364

Growth (%) : 8

blank

06

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Blood Disorders

Currency : USD

2018 Revenue in Millions : 1,679

2017 Revenue in Millions : 1,625

Growth (%) : 3%

blank

07

Brand Name : Pradaxa

Dabigatran Etexilate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pradaxa

arrow
2024 ACI Convention
Not Confirmed

Dabigatran Etexilate

Main Therapeutic Indication : Hematology

Currency : USD

2019 Revenue in Millions : 1,667

2018 Revenue in Millions : 1,620

Growth (%) : 3

blank

08

Brand Name : Pradaxa

Dabigatran Etexilate Mesylate

arrow
2024 ACI Convention
Not Confirmed